Stéphanie Clisant

2.4k total citations
55 papers, 1.5k citations indexed

About

Stéphanie Clisant is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Stéphanie Clisant has authored 55 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Stéphanie Clisant's work include Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (12 papers) and Cardiac tumors and thrombi (10 papers). Stéphanie Clisant is often cited by papers focused on Sarcoma Diagnosis and Treatment (19 papers), Vascular Tumors and Angiosarcomas (12 papers) and Cardiac tumors and thrombi (10 papers). Stéphanie Clisant collaborates with scholars based in France, United States and Belgium. Stéphanie Clisant's co-authors include Nicolas Penel, Charles Fournier, Jean‐Yves Blay, Nicolás Isambert, Antoîne Italiano, Christine Chevreau, Emmanuelle Bompas, Y Robin, Antoine Adenis and Sophie Piperno‐Neumann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Stéphanie Clisant

55 papers receiving 1.5k citations

Peers

Countries citing papers authored by Stéphanie Clisant

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Clisant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Clisant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Clisant more than expected).

Fields of papers citing papers by Stéphanie Clisant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Clisant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Clisant. The network helps show where Stéphanie Clisant may publish in the future.

Co-authorship network of co-authors of Stéphanie Clisant

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Clisant. A scholar is included among the top collaborators of Stéphanie Clisant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Clisant. Stéphanie Clisant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers 2018 ·BMC Cancer ·(unknown), C. Mariette, Florence Renaud, Guillaume Piessen, Patrick Gelé, Marie‐Christine Copin, Emmanuelle Leteurtre, (unknown), (unknown), Stéphanie Clisant, Valentin Harter, Franck Bonnetain, Alain Duhamel, Véronique Christophe, Antoine Adenis	13
2	Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO) 2016 ·Annals of Oncology ·Loïc Lebellec, François Bertucci, Emmanuelle Tresch‐Bruneel, Emmanuelle Bompas, Yves Toiron, Luc Camoin, Olivier Mir, Valérie Laurence, Stéphanie Clisant, (unknown), Jean‐Yves Blay, Anthony Gonçalvès, Nicolas Penel	1
3	Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS) 2016 ·Annals of Oncology ·Nuria Kotecki, Axel Le Cesne, Emmanuelle Tresch‐Bruneel, Olivier Mir, Christine Chevreau, François Bertucci, Corinne Delcambre, Esma Saâda-Bouzid, Sophie Piperno‐Neumann, Jacques Olivier Bay, (unknown), Thomas Ryckewaert, Nicolás Isambert, Antoîne Italiano, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel	4
4	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial 2015 ·The Lancet Oncology ·Axel Le Cesne, Jean‐Yves Blay, Julien Dômont, Emmanuelle Tresch‐Bruneel, Christine Chevreau, François Bertucci, Corinne Delcambre, Esma Saâda-Bouzid, Sophie Piperno‐Neumann, Jacques‐Olivier Bay, Olivier Mir, Isabelle Ray‐Coquard, Thomas Ryckewaert, Thibaud Valentin, Nicolás Isambert, Antoîne Italiano, Stéphanie Clisant, Nicolas Penel	63
5	Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis 2014 ·European Journal of Cancer ·S. Taïeb, Esma Saâda-Bouzid, Emmanuelle Tresch, Thomas Ryckewaert, Emmanuelle Bompas, Antoîne Italiano, Cécile Guillemet, (unknown), Sophie Piperno‐Neumann, A. Thyss, C. Maynou, Stéphanie Clisant, Nicolas Penel	22
6	A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours 2013 ·British Journal of Cancer ·Antoine Adenis, Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Chauzit, B. Bui-Nguyen, Jean‐Yves Blay, Emmanuelle Tresch‐Bruneel, Charles Fournier, Stéphanie Clisant, Éric Amela, Philippe A. Cassier, Mathiéu Molimard, Nicolas Penel	21
7	Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome 2013 ·BMC Cancer ·Antoine Adenis, Emmanuelle Tresch, S. Dewas, Olivier Romano, Mathieu Messager, Éric Amela, Stéphanie Clisant, Andrew Kramar, C. Mariette, X. Mirabel	29
8	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) 2012 ·The Oncologist ·Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, Axel Le Cesne, Y Robin, Christine Chevreau, Jacques‐Olivier Bay, Guilhem Bousquet, Sophie Piperno‐Neumann, Nicolás Isambert, L. Lemaître, Charles Fournier, Eric Gauthier, Olivier Collard, Didier Cupissol, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel, (unknown)	148
9	French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3 2012 ·Supportive Care in Cancer ·Florence Joly, Marie Lange, Olivier Rigal, Hildeberto Correia, Bénédicte Giffard, Jennifer L. Beaumont, Stéphanie Clisant, Lynne I. Wagner	67
10	Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials 2010 ·Investigational New Drugs ·Nicolas Penel, Alain Duhamel, Antoine Adenis, Patrick Devos, Nicolás Isambert, Stéphanie Clisant, Jacques Bonneterre	5
11	Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy 2010 ·Investigational New Drugs ·Amélie Lansiaux, (unknown), (unknown), Stéphanie Clisant, Nicolas Penel	14
12	Participation in randomised clinical trials is linked to emotion regulation strategies 2010 ·Contemporary Clinical Trials ·Tanguy Leroy, Véronique Christophe, Nicolas Penel, Stéphanie Clisant, Pascal Antoine	3
13	Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care 2010 ·British Journal of Cancer ·Nicolas Penel, Stéphanie Clisant, Éric Dansin, Christophe Desauw, M. Degardin, Laurent Mortier, Marie Vanhuyse, F. Bonodeau, Charles Fournier, (unknown), Antoine Adenis	22
14	Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs 2010 ·Investigational New Drugs ·Nicolas Penel, Antoine Adenis, Stéphanie Clisant, Jacques Bonneterre	26
15	Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies — The Pre-Optimon study 2010 ·Contemporary Clinical Trials ·Valérie Journot, Jean‐Pierre Pignon, Claude Gaultier, (unknown), (unknown), Bruno Giraudeau, Pierre‐Marie Preux, Jean‐Marc Tréluyer, Sylvie Chevret, V. Plattner, Claire Thalamas, Stéphanie Clisant, Philippe Ravaud, Geneviève Chêne	32
16	Prognostic factors for adult sarcomas of head and neck 2008 ·International Journal of Oral and Maxillofacial Surgery ·Nicolas Penel, Y. Mallet, Y Robin, Charles Fournier, Jessica Grosjean, L. Ceugnart, Stéphanie Clisant, J.-L. Lefebvre	34
17	Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis 2007 ·Supportive Care in Cancer ·Nicolas Penel, S. Dewas, (unknown), Stéphanie Clisant, Yazdan Yazdanpanah, Antoine Adenis	22
18	Risk factors for early catheter‐related infections in cancer patients 2007 ·Cancer ·Nicolas Penel, (unknown), Stéphanie Clisant, (unknown), Patrick Devos, Yazdan Yazdanpanah	50
19	A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa 2006 ·Oral Oncology ·Nicolas Penel, Éric Amela, Y. Mallet, (unknown), Stéphanie Clisant, (unknown), (unknown), (unknown), Jean‐Louis Lefebvre	12
20	Prognosis of hypercalcemia in aerodigestive tract cancers: Study of 136 recent cases 2005 ·Oral Oncology ·Nicolas Penel, Céline Berthon, (unknown), (unknown), Stéphanie Clisant, Michele Nguyen, Stéphanie Villet, Charles Fournier, Jean‐Louis Lefebvre	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact